Trek Financial LLC Acquires New Holdings in TransMedics Group, Inc. $TMDX

Trek Financial LLC acquired a new stake in TransMedics Group, Inc. (NASDAQ:TMDX) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 143,667 shares of the company’s stock, valued at approximately $11,989,000. Trek Financial LLC owned approximately 0.42% of TransMedics Group at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Dimensional Fund Advisors LP lifted its position in shares of TransMedics Group by 5.5% during the 1st quarter. Dimensional Fund Advisors LP now owns 516,679 shares of the company’s stock valued at $51,355,000 after buying an additional 26,969 shares in the last quarter. Braidwell LP increased its holdings in TransMedics Group by 85.1% in the 2nd quarter. Braidwell LP now owns 609,715 shares of the company’s stock worth $40,497,000 after acquiring an additional 280,324 shares in the last quarter. Wellington Management Group LLP increased its holdings in TransMedics Group by 6.1% in the 2nd quarter. Wellington Management Group LLP now owns 515,973 shares of the company’s stock worth $34,271,000 after acquiring an additional 29,500 shares in the last quarter. Principal Financial Group Inc. raised its position in TransMedics Group by 19.4% during the first quarter. Principal Financial Group Inc. now owns 231,433 shares of the company’s stock worth $23,007,000 after acquiring an additional 37,656 shares during the period. Finally, Congress Asset Management Co. raised its position in TransMedics Group by 11.0% during the third quarter. Congress Asset Management Co. now owns 252,952 shares of the company’s stock worth $21,109,000 after acquiring an additional 25,118 shares during the period. 99.67% of the stock is owned by institutional investors and hedge funds.

TransMedics Group Price Performance

Shares of NASDAQ TMDX opened at $65.99 on Monday. The firm has a 50-day simple moving average of $81.65 and a 200-day simple moving average of $94.92. The stock has a market capitalization of $2.28 billion, a price-to-earnings ratio of 16.96, a price-to-earnings-growth ratio of 0.91 and a beta of 2.14. The company has a quick ratio of 6.07, a current ratio of 6.62 and a debt-to-equity ratio of 1.62. TransMedics Group, Inc. has a 52 week low of $60.10 and a 52 week high of $156.00.

TransMedics Group (NASDAQ:TMDX) last posted its quarterly earnings results on Tuesday, August 4th. The company reported $0.44 earnings per share for the quarter, missing the consensus estimate of $0.50 by ($0.06). TransMedics Group had a return on equity of 15.88% and a net margin of 22.69%. The business had revenue of $189.95 million during the quarter, compared to analysts’ expectations of $184.00 million. During the same period in the prior year, the business posted $0.92 earnings per share. The business’s quarterly revenue was up 20.7% on a year-over-year basis. On average, equities analysts predict that TransMedics Group, Inc. will post 1.46 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on the stock. UBS Group dropped their target price on shares of TransMedics Group from $80.00 to $77.00 and set a “neutral” rating on the stock in a research report on Wednesday, August 5th. Weiss Ratings upgraded shares of TransMedics Group from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, August 31st. Canaccord Genuity Group reduced their price target on shares of TransMedics Group from $95.00 to $94.00 and set a “buy” rating for the company in a research report on Tuesday, October 13th. Barclays started coverage on shares of TransMedics Group in a research note on Wednesday, October 7th. They issued an “overweight” rating and a $120.00 price target on the stock. Finally, Needham & Company LLC reiterated a “buy” rating on shares of TransMedics Group in a report on Friday, September 11th. Five investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, TransMedics Group currently has a consensus rating of “Hold” and an average price target of $115.60.

Insiders Place Their Bets

In other TransMedics Group news, Director David Weill bought 1,336 shares of the firm’s stock in a transaction on Friday, September 11th. The shares were acquired at an average cost of $81.63 per share, with a total value of $109,057.68. Following the purchase, the director directly owned 16,392 shares of the company’s stock, valued at $1,338,078.96. This trade represents a 8.87% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. 6.90% of the stock is owned by company insiders.

TransMedics Group Profile

TransMedics Group, Inc is a medical technology company focused on improving organ transplantation through systems that preserve and assess donor organs outside the body. The company’s primary platform is the Organ Care System (OCS), a portable, technology-enabled perfusion system designed to maintain organs in a functioning, near-physiologic state during transport and evaluation.

TransMedics offers OCS products for heart, lung and liver transplantation. Its systems are intended to support the use of organs that may not otherwise be suitable for conventional cold-storage methods, potentially expanding the donor pool and providing transplant teams with additional information when evaluating organs for transplantation.

Founded in 1998 and headquartered in Andover, Massachusetts, TransMedics serves transplant centers in the United States and select international markets.